Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 23:15:1348852.
doi: 10.3389/fimmu.2024.1348852. eCollection 2024.

Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

Yilan Xu  1 , Panruo Jiang  2 , Zhenyan Xu  1 , Haige Ye  1
Affiliations
Review

Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

Yilan Xu et al. Front Immunol. .

Abstract

CD47 is a cell-surface ligand that is overexpressed in various malignancies and that binds to SIRPα on macrophages to promote tumor cell evasion of phagocytosis. Blocking the CD47-SIRPα axis can increase the phagocytosis of macrophages to exert antitumor effects. CD47-based immunotherapy is a current research focus. The combination of anti-CD47 antibodies with other drugs has shown encouraging response rates in patients with hematological tumors, but side effects also occur. Bispecific antibodies and SIRPα/Fc fusion proteins appear to balance the efficacy and safety of treatment. We review the latest clinical research advances and discuss the opportunities and challenges associated with CD47-based immunotherapy for hematological malignancies.

Keywords: anti-CD47 antibody; cd47; hematological malignancies; immunotherapy; magrolimab.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The mechanism of CD47-based immunotherapy. (A) CD47 expressed on tumor cells binds to SIRPα on macrophages to activate the “don’t eat me” signal to enable tumor cells to escape macrophage-mediated phagocytosis. (B) Anti-CD47 monoclonal antibody, anti-SIRPα antibody, recombinant SIRPα protein and bispecific antibody inhibit the CD47-SIRPα interaction, leading to macrophage phagocytosis of tumor cells.
See this image and copyright information in PMC

References

    1. Tang L, Huang Z, Mei H, Hu Y. Immunotherapy in hematologic Malignancies: achievements, challenges and future prospects. Signal Transduction Targeted Ther (2023) 8:306. doi: 10.1038/s41392-023-01521-5 - DOI - PMC - PubMed
    1. Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica (2023) 108:308–20. doi: 10.3324/haematol.2022.280801 - DOI - PMC - PubMed
    1. Wang HW, Balakrishna JP, Pittaluga S, Jaffe ES. Diagnosis of hodgkin lymphoma in the modern era. Br J Haematol (2019) 184:45–59. doi: 10.1111/bjh.15614 - DOI - PMC - PubMed
    1. Ansell SM. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc (2015) 90:1574–83. doi: 10.1016/j.mayocp.2015.07.005 - DOI - PubMed
    1. Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-hodgkin lymphoma. Lancet (London England) (2017) 390:298–310. doi: 10.1016/s0140-6736(16)32407-2 - DOI - PubMed

Publication types